Xolair, Nucala, Fasenera, Dupixent
Xolair (omalizumab), a biologic agent that targets IGE, is used to treat moderate to severe asthma in ages 6 and above. Xolair is also used to treat chronic hives (idiopathic urticaria) in ages > 12 and nasal polyps in adults.
Nucala (mepolizumab) is used to treat severe asthma in patients with elevated eosinophils in ages > 6, Hypereosinophilic Eosinophilic Syndrome (HES) in ages > 12, as well as Eosinophilic Granulomatosis with Polyangitis (EGPA) and Chronic Rhinitis with Nasal Polyps (CRSwNP) in adults
Fasenera (benralizumab) is also used to treat moderate severe asthma in adults who have elevated eosinophil counts.’
Dupixent (dupilumab) is a biologic agent used to treat moderate to severe atopic dermatitis in ages > 6 , moderate to severe asthma with elevated eosinophils in ages > 12 , and CRSwNP in adults.